Saya Biologics

Saya Biologics is a clinical-stage biotechnology company dedicated to the discovery and development of novel biologics for oncology and immunological disorders. The company's primary focus is on the "don't eat me" signal pathway, specifically targeting the CD47-SIRPα axis to promote anti-tumor immune responses. Its lead program, SAYA-121, is a humanized monoclonal antibody designed to block CD47 with high potency while maintaining a favorable safety profile regarding hemagglutination. Based in Palo Alto, California, Saya Biologics utilizes advanced protein engineering to optimize the therapeutic window of its candidates. The company's pipeline includes additional programs aimed at modulating innate and adaptive immunity to treat refractory cancers.